Navigation Links
Stem cell mobilization therapy appears to be ineffective in repairing damage caused by heart attack

Therapy that involved bone marrow stem cells did not improve cardiac function in patients following a heart attack, according to a study in the March 1 issue of JAMA.

There has been increasing evidence that stem cells contribute to regeneration of cardiac tissue and the development of new blood vessels following a heart attack, thus opening up new prospects for stem-cell based therapies. Granulocyte colony-stimulating factor (G-CSF, a growth-factor protein) induces mobilization of bone marrow stem cells, according to background information in the article.

Dietlind Zohlnhöfer, M.D., of the Technische Universität, Munich, Germany, and colleagues conducted a randomized, double-blind, placebo-controlled study (REVIVAL-2) to assess the value of G-CSF treatment in a large group of patients following a heart attack. The 114 patients, diagnosed with ST-segment elevation acute myocardial infarction (a certain pattern on an electrocardiogram indicating a heart attack), had successful reperfusion (restoration of blood flow) to the heart by percutaneous coronary intervention (procedures such as angioplasty in which a catheter-guided balloon is used to open a narrowed coronary artery) within 12 hours after onset of symptoms. Patients were randomly assigned to receive by injection either a daily dose of 10 µg/kg of G-CSF or placebo (an inactive substance) for 5 days. The patients were treated between February 2004 and February 2005.

Treatment with G-CSF produced a significant mobilization of bone marrow stem cells. The researchers found that this did not alter infarct size (area of damage) or left ventricular function after a heart attack. "Moreover, in contrast to other studies, no increase in the risk of restenosis (narrowing again of an artery after treatment) or major adverse cardiac events was observed with G-CSF treatment," the authors write.

"The REVIVAL-2 trial had a cohort that was larger than all 3 previous trials taken together and had a relatively long follow-up period based on sensitive assessment methods of left ventricular function and infarct size. In conclusion, use of G-CSF therapy to mobilize bone marrow–derived stem cell does not improve left ventricular recovery in patients with acute myocardial infarction after successful mechanical reperfusion," they write.


'"/>

Source:JAMA and Archives Journals


Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/2/2019)... ... January 31, 2019 , ... Through its ... research support in study design, planning, sample collection, and analysis to researchers at ... Gynecology, and Dr. Sara Vaughn, MD, Reproductive Endocrinology and Infertility Fellow, to study ...
(Date:1/25/2019)... ... 2019 , ... GrowthZone, Inc., provider of association ... indicates membership growth in some sectors and decreasing membership among others. , The ... over 500 association professionals across North America. , “This year’s survey shed ...
(Date:1/20/2019)... ... January 16, 2019 , ... ... doc.ai, a medical research platform that uses artificial intelligence (AI) and a data-centric ... for Crohn’s disease and ulcerative colitis. , People will Crohn’s or other chronic ...
Breaking Biology News(10 mins):
(Date:2/2/2019)... ... February 01, 2019 , ... ... the appointment of its new CEO, Julien Dert, being effective on February 1st, ... experience in finance and management, in which more than 12 years in the ...
(Date:1/30/2019)... , ... January 29, 2019 , ... ... Development and Manufacturing Organization (CDMO) serving the global biopharmaceutical and biotechnology industries with ... of $59.1 million backed by multiple global investors lead by China's State Development ...
(Date:1/30/2019)... ... January 29, 2019 , ... Actus Therapeutics, a privately ... the first patient in a phase 1/2 clinical study of ACTUS-101 in patients ... morbidity and often leads to premature death. There are variable rates of ...
(Date:1/30/2019)... ... January 29, 2019 , ... Could a computer detect ... a tricky math problem on an online tutoring program? Could it detect deep ... computer science assistant professor Erin Solovey is working to develop a ...
Breaking Biology Technology: